Pedersen L M, Milman N
Medicinsk-lungemedicinsk afdeling Y, Amtssygehuset i Gentofte.
Ugeskr Laeger. 1998 Jun 22;160(26):3917-20.
The prognostic information provided by platelet counts was studied in 1115 patients with primary lung cancer and in 550 control patients with benign lung disorders. Patient records were retrospectively reviewed regarding histological tumour type, TNM stage, thromboembolic episodes and survival. The prevalence of thrombocytosis (platelet count > 400 x 10(9)/l) in patients with lung cancer was 32.1% vs. 6.4% in controls (p < 0.0001). Platelet counts increased with TNM stage (p < 0.0001). Patients with thrombocytosis had a shorter survival than patients with normal platelet count (p < 0.0001). Thrombocytosis was a predictor of short survival also when adjusted for tumour type, sex, age, and TNM stage (p < 0.001). The platelet count and the frequency of thrombocytosis declined after tumour resection (p < 0.0001). Thrombocytosis was not associated with thromboembolism. In conclusion, thrombocytosis is a clinically significant prognostic indicator regarding survival in patients with primary lung cancer.
在1115例原发性肺癌患者和550例良性肺部疾病对照患者中研究了血小板计数提供的预后信息。回顾性分析患者记录，内容包括组织学肿瘤类型、TNM分期、血栓栓塞事件和生存率。肺癌患者中血小板增多症（血小板计数>400×10⁹/L）的患病率为32.1%，而对照组为6.4%（p<0.0001）。血小板计数随TNM分期增加而升高（p<0.0001）。血小板增多症患者的生存期短于血小板计数正常的患者（p<0.0001）。在对肿瘤类型、性别、年龄和TNM分期进行校正后，血小板增多症仍是生存期短的一个预测因素（p<0.001）。肿瘤切除后血小板计数和血小板增多症的发生率下降（p<0.0001）。血小板增多症与血栓栓塞无关。总之，血小板增多症是原发性肺癌患者生存的一个具有临床意义的预后指标。
